Wellington Management Group
PCVX icon

Wellington Management Group’s Vaxcyte PCVX Stock Holding History

Wellington Management Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407M Buy
7,001,565
+1,386,968
+25% +$75.3M 0.07% 252
2026
Q1 		$326M Sell
5,614,597
-351,713
-6% -$19.1M 0.06% 270
2025
Q4 		$275M Buy
5,966,310
+933,539
+19% +$41.8M 0.05% 316
2025
Q3 		$181M Buy
5,032,771
+77,967
+2% +$2.58M 0.03% 407
2025
Q2 		$161M Sell
4,954,804
-1,462,126
-23% -$47.9M 0.03% 403
2025
Q1 		$242M Buy
6,416,930
+1,972,918
+44% +$158M 0.05% 302
2024
Q4 		$364M Sell
4,444,012
-69,744
-2% -$6.93M 0.07% 241
2024
Q3 		$516M Sell
4,513,756
-79,310
-2% -$7.15M 0.09% 198
2024
Q2 		$347M Sell
4,593,066
-326,304
-7% -$22.2M 0.06% 266
2024
Q1 		$336M Buy
4,919,370
+487,450
+11% +$33.8M 0.06% 298
2023
Q4 		$278M Sell
4,431,920
-166,792
-4% -$8.66M 0.05% 322
2023
Q3 		$234M Buy
4,598,712
+167,501
+4% +$8.26M 0.05% 333
2023
Q2 		$221M Buy
4,431,211
+1,191,937
+37% +$56.5M 0.04% 369
2023
Q1 		$121M Sell
3,239,274
-288,840
-8% -$12.3M 0.02% 498
2022
Q4 		$169M Buy
3,528,114
+1,779,193
+102% +$69.8M 0.03% 421
2022
Q3 		$42M Buy
1,748,921
+1,619,700
+1,253% +$41.1M 0.01% 711
2022
Q2 		$2.81M Sell
129,221
-1,015,594
-89% -$23.5M ﹤0.01% 1473
2022
Q1 		$27.6M Sell
1,144,815
-8,210
-0.7% -$179K ﹤0.01% 939
2021
Q4 		$27.4M Buy
1,153,025
+114,804
+11% +$2.67M ﹤0.01% 1004
2021
Q3 		$26.3M Buy
1,038,221
+160,096
+18% +$3.88M ﹤0.01% 1006
2021
Q2 		$19.8M Sell
878,125
-120,285
-12% -$2.46M ﹤0.01% 1096
2021
Q1 		$19.7M Sell
998,410
-12,440
-1% -$313K ﹤0.01% 1079
2020
Q4 		$26.9M Sell
1,010,850
-87,006
-8% -$3.23M ﹤0.01% 965
2020
Q3 		$54.2M Sell
1,097,856
-102,144
-9% -$4.07M 0.01% 676
2020
Q2 		$37.9M Buy
+1,200,000
New +$38.6M 0.01% 768

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group's PCVX Position: Q2 2026 in Review

Wellington Management Group increased its Vaxcyte (PCVX) stake by 25% in Q2 2026, buying an estimated $75.3M and bringing the position to 7,001,565 shares worth $407M. The position accounts for 0.07% of the portfolio, ranked #252.

Wellington Management Group first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $516M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Wellington Management Group held 7,001,565 shares of Vaxcyte worth $407M as of Q2 2026.
  • Wellington Management Group bought 1,386,968 Vaxcyte shares in Q2 2026, an estimated $75.3M.
  • Vaxcyte made up 0.07% of Wellington Management Group's portfolio in Q2 2026, its #252 holding.
  • Wellington Management Group first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • Wellington Management Group's Vaxcyte position peaked at $516M in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.